Brief: Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China
28/08/2026 01:38
BRIEF-Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China Aug 28 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ANNOUNCES NMPA CONDITIONAL APPROVAL FOR ATLED (FANTEGRATINIB) IN CHINA
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsKras: EGFR-Antibody licensing deal with GSK closes
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals